Challenges in achieving optimal glycemic control in type 2 diabetes patients with declining renal function: The Southeast Asia perspective

Journal of Diabetes Investigation

Volumn 3, Issue 6, 2012, Pages 481-489

  Cc Chow, Francis ^a   Chan, Siew Pheng ^b   Hwu, Chii Min ^c   Suwanwalaikorn, Sompongse ^d   Wu, Akira Yt ^e   Gan, Susan Yu ^f   Zacarias, Manuel B ^g  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY MALAYA MEDICAL CENTRE   (Malaysia)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^d CHULALONGKORN UNIVERSITY   (Thailand)

^e MOUNT ELIZABETH MEDICAL CENTRE   (Singapore)

^f Metropolitan Medical Center   (Philippines)

^g UNIVERSITY OF SANTO TOMAS   (Philippines)

Author keywords

Chronic kidney disease; Dipeptidyl peptidase IV inhibitors; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; DAPAGLIFLOZIN; EMPAGLIFLOZIN; EXENDIN 4; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; INCRETIN; INSULIN; LINAGLIPTIN; LIRAGLUTIDE; METFORMIN; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; REPAGLINIDE; SAXAGLIPTIN; SITAGLIPTIN; VILDAGLIPTIN;

CHRONIC KIDNEY DISEASE; CLINICAL FEATURE; DIABETES CONTROL; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG USE; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; KIDNEY FAILURE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT CARE; PRIORITY JOURNAL; PUBLIC HEALTH PROBLEM; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SOUTHEAST ASIA; TREATMENT INDICATION;

EID: 84871659861     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/jdi.12006     Document Type: Review

References (82)

1. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes. Estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-1053.
2. International Diabetes Federation. Foreword Available at: http://www.diabetesatlas.org/content/foreword-0 (accessed 30 May 2011).
3. Chan JC, Malik V, Jia W, et al. Diabetes in Asia. Epidemiology, risk factors, and pathophysiology. JAMA 2009; 301: 2129-2140.
4. World Health Organization. Noncommunicable Diseases. Available at: http://www.searo.who.int/en/Section1174/Section1459_7409.htm (accessed 2 July 2011).
5. Wong KC, Whang Z. Prevalence of Type 2 diabetes mellitus of Chinese populations in mainland China, Hong Kong, and Taiwan. Diabetes Res Clin Pract 2006; 73: 126-134.
6. Leung G, Lam K. Diabetic complications and their implications on health care in Asia. Hong Kong Med J 2000; 6: 61-68.
7. Fowler M. Microvascular and macrovascular complications of diabetes. Clin Diabetes 2008; 26: 77-82.
8. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001; 414: 782-787.
9. Woodward M, Zhang X, Barzi F, et al. The effects of diabetes on the risks of major cardiovascular diseases and death in the Asia-Pacific region. Diabetes Care 2003; 26: 360-366.
10. Economic Impact of Diabetes. IDF Diabetes Atlas Fourth Edition. Available at: http://www.diabetesatlas.org/content/economic-impacts-diabetes (accessed 4 June 2011).
11. Yang W, Lu J, Weng J, et al. Prevalence of diabetes among men and women in China. N Engl J Med 2010; 362: 1090-1100.
12. Lin T, Chou P, Lai MS, et al. Direct costs-of-illness of patients with diabetes mellitus in Taiwan. Diabetes Res Clin Pract 2001; 54(Suppl 1): S43-S46.
13. Chan BSW, Tsang MW, Lee VW, et al. Cost of type 2 diabetes mellitus in Hong Kong Chinese. Int J Clin Pharmacol Ther 2007; 45: 455-468.
14. Goldhaber-Fiebert JD, Li H, Ratanawijitrasin S, et al. Inpatient treatment of diabetic patients in Asia: evidence from India, China, Thailand and Malaysia. Diabetes Metab 2010; 27: 101-108.
15. Yoon KH, Lee JH, Kim JW, et al. Epidemic obesity and type 2 diabetes in Asia. Lancet 2006; 368: 1681-1688.
16. Chen KW, Boyko EJ, Bergstrom RW, et al. Earlier appearance of impaired insulin secretion than of visceral adiposity in the pathogenesis of NIDDM. 5-Year follow-up of initially nondiabetic Japanese-American men. Diabetes Care 1995; 18: 747-753.
17. Matsumoto K, Miyake S, Yano M, et al. Glucose tolerance, insulin secretion, and insulin sensitivity in nonobese and obese Japanese subjects. Diabetes Care 1997; 20: 1562-1568.
18. Yajnik CS. Early life origins of insulin resistance and type 2 diabetes in India and other Asian countries. J Nutr 2004; 134: 205-210.
19. Radha V, Mohan V. Genetic predisposition to type 2 diabetes among Asian Indians. Indian J Med Res 2007; 125: 259-274.
20. Toh MPHS, Wu CX, Leong HSS, et al. Association of younger age with poor glycemic and cholesterol control in Asians with type 2 diabetes mellitus in Singapore. J Endocrinol Metab 2011; 1: 27-37.
21. Asia Pacific Cohort Studies Collaboration. The effects of diabetes on the risks of major cardiovascular diseases and death in the Asia-Pacific Region. Diabetes Care 2003; 26: 360-366.
22. Wu AY, Kong NC, de Leon FA, et al. An alarmingly high prevalence of diabetic nephropathy in Asian type 2 diabetic patients: the MicroAlbuminuria Prevalence (MAP) study. Diabetologia 2005; 48: 17-26.
23. Luk A, Chan JCN. Diabetic nephropathy - what are the unmet needs? Diabetes Res Clin Pract 2008; 82: S15-S20.
24. K/DOQIWork Group. Clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Part 4. Definition and classification of stages of chronic kidney disease. Am J Kidney Dis 2002; 39: s46-s75.
25. Levey AS, de Jong PE, Coresh J, et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int 2011; 80: 17-28.
26. Domrongkitchaiporn S, Sritara P, Kitiyakara C, et al. Risk factors for development of decreased kidney function in a Southeast Asian population: a 12-year cohort study. J Am Soc Nephrol 2005; 16: 791-799.
27. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 1984; 310: 356-360.
28. Yeung VT, Lee KF, Chan SH, et al. Microalbuminuria Prevalence Study (MAPS) in hypertensive type 2 diabetic patients in Hong Kong. Hong Kong Med J 2006; 12: 185-190.
29. Sia'bani M, Asdie AH, Widayati K, et al. Microalbuminuria prevalence study in hypertensive patients with type 2 diabetes in Indonesia. Acta Med Indones 2005; 37: 199-204.
30. Kong N, Chia YC, Khalid BA, et al. Microalbuminuria prevalence study in hypertensive type 2 diabetic patients in Malaysia. Med J Malaysia 2006; 61: 457-465.
31. Buranakitjaroen P, Deerochanawong C, Bunnag P. Microalbuminuria prevalence study (MAPS) in hypertensive patients with type 2 diabetes in Thailand. J Med Assoc Thai 2005; 88: 1624-1629.
32. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193-203.
33. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837-853.
34. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589.
35. Shichiri M, Kishikawa H, Ohkubo Y, et al. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000; 23(Suppl 2): B21-B29.
36. Gaede P, Vedel P, Parving HH, et al. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 1999; 353: 617-622.
37. Gaede P, Lund-Andersen H, Parving HH, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358: 580-591.
38. Zoungas S, de Galan BE, Ninomiya T, et al. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: new results from the ADVANCE trial. Diabetes Care 2009; 32: 2068-2074.
39. Tu ST, Chang SJ, Chen JF, et al. Prevention of diabetic nephropathy by tight target control in an Asian population with type 2 diabetes mellitus. Arch Intern Med 2010; 170: 155-161.
40. Hseih MC, Hseih YT, Cho TJ, et al. Remission of diabetic nephropathy i n type 2 diabetic Asian population: role of tight glucose and blood pressure control. Eur J Clin Invest 2011; 41: 870-878.
41. Dalla Vestra M, Saller A, Bortoloso E. Structural involvement in type 1 and type 2 diabetic nephropathy. Diabetes Metab 2000; 26(Suppl 4): 8-14.
42. Karter AJ, Ferrara A, Liu JY, et al. Ethnic disparities in diabetic complications in an insured population. JAMA 2002; 287: 2519-2527.
43. US Renal Data System, USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2010.
44. Singapore Health Promotion Board. Information Paper on End-Stage Renal Disease. March 2011. National Registry of Diseases Office. Available at: http://www.nrdo.gov.sg/
45. Bakris G, Ritz E. The message for World Kidney Day 2009: hypertension and kidney disease: a marriage that should be prevented. J Clin Hypertens (Greenwich) 2009; 11: 144-147.
46. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease. Circulation 2003; 108: 2154-2169.
47. Levey AS, Astor BC, Stevens LA, et al. Chronic kidney disease, diabetes, and hypertension: what's in a name? Kidney Int 2010; 78: 19-22.
48. Epstein M, Sowers JR. Diabetes mellitus and hypertension. Hypertension 1992; 19: 403-418.
49. Stamler J, Vaccaro O, Neaton JD, et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care 1993; 46: 434-444.
50. Liu Z, Fu C, Wang W, et al. Prevalence of chronic complications of type 2 diabetes mellitus in outpatients - a cross-sectional hospital based survey in urban China. Health Qual Life Outcomes 2010; 8: 62.
51. Chan JC, Malik V, Jia W, et al. Diabetes in Asia. Epidemiology, risk factors, and pathophysiology. Diabetes Care 2009; 32: 227-233.
52. Lindeman RD. Is the decline in renal function with normal aging inevitable? Kidney Int 1984; 26: 861-868.
53. Ribstein J, Du Cailar G, Mimran A. Glucose tolerance and age-associated decline in renal function of hypertensive patients. J Hypertens 2001; 19: 2257-2264.
54. Tong PCY, Ko GTC, So WY, et al. Use of anti-diabetic drugs and glycemic control in type 2 diabetes - the Hong Kong Diabetes Registry. Diabetes Res Clin Pract 2008; 82: 346-352.
55. Cavanaugh K. Diabetes management issues for patients with chronic kidney disease. Clin Diabetes 2007; 25: 90-97.
56. Moen MF, Zhan M, Hsu VD, et al. Frequency of hypoglycemia and its significance in chronic kidney disease. Clin J Am Soc Nephrol 2009; 4: 1121-1127.
57. National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 2007; 2: S12-S154.
58. American Diabetes Association. Clinical practice guidelines. Diabetes Care 2012; 35: S11-S63.
59. Zelmanovitz T, Gerchman F, Balthazar AP, et al. Diabetic nephropathy. Diabetol Metab Syndr 2009; Sep 21; 1: 10.
60. International Diabetes Federation. Diabetes Atlas, 3rd edn. International Diabetes Federation, Brussels, 2006.
61. Krepinsky J, Ingram AJ, Clase CM. Prolonged sulfonylurea-induced hypoglycemia in diabetic patients with end-stage renal disease. Am J Kidney Dis 2000; 35: 500-505.
62. Lubowsky ND, Siegel R, Pittas AG. Management of glycemia in patients with diabetes mellitus and CKD. Am J Kidney Dis 2007; Nov; 50: 865-879.
63. Bolen S, Feldman L, Vassy J, et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 2007; 147: 386-399.
64. Bakris G, Viberti G, Weston WM, et al. Rosiglitazone reduces urinary albumin excretion in type II diabetes. J Hum Hypertens 2003; 17: 7-12.
65. Imano E, Kanda T, Nakatani Y, et al. Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy. Diabetes Care 1998; 21: 2135-2139.
66. Nakamura T, Ushiyama C, Suzuki S, et al. Effect of troglitazone on urinary albumin excretion and serum type IV collagen concentrations in Type 2 diabetic patients with microalbuminuria or macroalbuminuria. Diabet Med 2001; 18: 308-313.
67. Thomas L, Tadayyon M, Mark M, et al. Chronic treatment with the dipeptidyl peptidase-4 inhibitor BI 1356 [(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3, 7-dihydro-purine-2, 6-dione] increases basal glucagon-like peptide-1 and improves glycemic control in diabetic rodent models. J Pharmacol Exp Ther 2009; 328: 556-563.
68. Khoo J, Rayner CK, Jones KL, et al. Incretin-based therapies: new treatments for type 2 diabetes in the new millennium. Ther Clin Risk Manag 2009; 5: 683-698.
69. Ahren B, Pacini G, Tura A, et al. Improved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes. Horm Metab Res 2007; 39: 826-829.
70. Ahren B, Pacini G, Foley JE, et al. Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care 2005; 28: 1936-1940.
71. Henry R, Smith S, Schwartz S, et al. ß-cell stimulation by saxagliptin in patients withT2D [abstract no. 447-P plus poster]. 69th Annual Scientific Sessions of the American Diabetes Association; 2009 Jun 5-9; New Orleans (LA)
72. Deacon C. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes Metab 2011; 13: 7-18.
73. Aschner P, Katzeff HL, Guo H, et al. Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes. Diabetes Obes Metab 2010; 12: 252-261.
74. Schweizer A, Dejager S, Bosi E, et al. Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Obes Metab 2009; 11: 804-812.
75. Ferrannini E, Fonseca V, Zinman B, et al. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab 2010; 11: 157-166.
76. Nauck A, Meininger G, Sheng D, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007; 9: 194-205.
77. Bolli G, Dotta F, Rochotte E, et al. Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study. Diabetes Obes Metab 2010; 10: 82-90.
78. Scott R, Loeys T, Davies MJ, et al. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes Obes Metab 2010; 10: 959-969.
79. Scheen AJ. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab 2010; 12: 648-658.
80. Blech J, Ludwig-Schwellinger E, Gräfe-Mody EU, et al. The metabolism and disposition of oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans. Drug Metab Dispos 2010; 38: 667-678.
81. Heise T, Graefe-Mody EU, Hüttner S, et al. Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients. Diabetes Obes Metab 2009; 11: 786-794.
82. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology Consensus Panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009; 15: 541-559.